I agree and outside of a country issuing an EUA or some

New Post Public Reply Private Reply Replies (1) Message Board
sjacobs26 ohm20 #89078
537
I agree and outside of a country issuing an EUA or some deal to purchase 100,000 vials+ for CSP/IO or similar interim sales, this large powered trial is the best thing we could hope for (especially given the partnership with such a prestigious ARO and a country in dire need).......but like Craig and many others wish that leronlimab was saving thousands of lives already. Unfortunately this isn't an option at the moment for Brazil and likely other developed countries that are following the lead of the US FDA.

While I hope that interim results will be sooner than outlined, we don't yet know when the protocol will be finalized, when the trial will actually begin and how many sites will be enrolling or when more will begin recruiting. I expect the protocol to be much better than CD12, so there is a high probability of hitting stat significant p-value during interim analysis (CD12 was stat significant with 2 injections and N=62, so 4 injections and N=120, seems likely to hit it out of the park). The other positive thing for us investors with this trial is it begins the clock for what should be an EUA or approval for COVID and as the days count down to interim results, the share price should appreciate in anticipation similar to CD12 did in late 2020 and early 2021. I expect continued stock manipulation until we get other positive news or results, but at least a new trial is moving forward and can't ask for anything more from CYDY or Brazil other than issue a EUA, fast enrollment and many trial sites recruiting.

One last note, I am glad to see that severe is also being pursued. While it may not be as promising as critical, it is likely better than most other treatment options currently available, may keep some from advancing to critical (real life impacts) and if it shows even clinical significant results, will likely be used by treating physicians and increase sales exponentially when the day comes.

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

BETR's Slide: Investors Face Big Losses, Leadership Shift

Updated Category News Views 206

BETR Investors Left in the Lurch It's a real trainwreck, folks. Better Home & Finance Holding Company, trading under NASDAQ:BETR, is in the spotlight for all the wrong reasons. The company expanded the class period for its investor lawsuit to include even more dates between March and August 2026, reflecting a torturous ride for shareholders. Their stock cratered by a...

Continue Reading
Novo's Research Unlocks New Insights into Food Noise

Updated Category News Views 376

Unpacking the Science Behind Food Noise When folks think about losing weight, most picture shedding pounds and fitting into those elusive smaller jeans. But get this—there’s a curveball called ‘food noise’ that’s making waves in obesity treatment. Novo Nordisk’s semaglutide injections are shaking things up, cutting down on those persistent thoughts about food....

Continue Reading
WeaveGrid Powers EVConnectNC: Charging Incentives Launched

Updated Category News Views 177

Transforming Utilities with EVConnectNC In a fresh move by WeaveGrid, North Carolina's Electric Cooperatives have teamed up to roll out EVConnectNC. This innovative program aims to manage the burgeoning demand for electric vehicle (EV) charging in rural and suburban areas under North Carolina's cooperative umbrella. Think of it as a smart way to handle new loads without...

Continue Reading
Lilly's Obesity Breakthroughs: A Step Beyond the Scale

Updated Category News Views 243

Pushing the Boundaries of Obesity Treatment Alright, let's cut through the noise and get to what really matters here. Eli Lilly is taking on obesity treatment like it's Clash of the Titans at this year's ObesityWeek 2026 in Washington, D.C. Forget just dropping pounds—Lilly wants to reshape how we think about obesity entirely. They're not just leaning into the scale,...

Continue Reading
Webull Faces Class Action: Key Details for Investors

Updated Category News Views 254

What's Really Going on With Webull? When you hear there's a class-action lawsuit brewing, you know something's gone real sideways. Webull Corporation (NASDAQ: BULL) finds itself neck-deep in a securities fraud class action alleging some dicey dealings with China. If you've got skin in the game—and if you bought Webull stock between April 26, 2025, and October 6,...

Continue Reading
Servier's Data on Tovorafenib Shows Promise in pLGG

Updated Category News Views 433

New Light on a Critical Challenge Talk about a fight in the dark. Pediatric low-grade glioma (pLGG) is a menace that families dread, an uphill battle with odds that feel relentless. Enter Servier and its four-year updated data on OJEMDA® (tovorafenib), a beacon of hope for kids battling these tricky brain tumors. Results, presented at the SNO meeting, are fresh off the...

Continue Reading
El Pollo Loco Faces Class Action Over Wage Practices

Updated Category News Views 407

Alright, here's where things start sizzling—El Pollo Loco, the fast-food chicken chain whose name translates to 'The Crazy Chicken'—is in a legal pickle. The lawsuit hanging over their heads could spell a sticky situation for them and possibly ripple through the fast-food industry. The suit, filed by the steadfast firm Blumenthal Nordrehaug Bhowmik De Blouw LLP, has...

Continue Reading
HONGQI's EHS4 Launch in Europe: Bridging East and West

Updated Category News Views 168

Revving Up a New Chapter: HONGQI in Venice There's a new player in the European automotive scene, and it's rolling in with more style than a Venetian gondola. HONGQI, a name that's been turning gears in China since '58, is packing its suitcases full of Eastern elegance and landing straight in Venice with the all-electric EHS4. On November 16, the brand is set to unveil...

Continue Reading
Novo's CagriSema Trial Shows Promising Obesity Results

Updated Category News Views 392

Novo's Latest Weight Loss Gamble Well, look what we have here. Novo Nordisk is shaking up the obesity treatment scene with some bold numbers from their REDEFINE 9 trial. The investigational CagriSema combo of amylin analog and GLP-1 receptor agonist has churned out an eyeball-popping near 21% weight loss. For context, we're staring down the barrel of numbers far meatier...

Continue Reading
Advanta's Game-Changer: Acquiring Misr Hytech to Expand in Africa

Updated Category News Views 338

Advanta's Strategic Move into Africa Alright, let's cut to the chase. Advanta is making a big splash with its acquisition of Misr Hytech, a move that's going to shake things up in Africa's agricultural sector. This isn't just another merger to gloss over with your morning coffee. We're talking about a deal that's supposed to wrap up by January 31, 2027, bringing together...

Continue Reading

Top 5 Most Recently Viewed Articles

Viatris Launches Cash Tender Offers for Outstanding Notes

Updated Category News Views 56

Viatris Launches Cash Tender Offers for Outstanding Notes Viatris Inc. (NASDAQ: VTRS), a leading player in the global healthcare sector, has initiated tender offers to acquire certain outstanding notes. This move is designed to strengthen its financial framework and enhance returns for its shareholders. Notably, the offers include various senior notes that were originally...

Continue Reading
Coke Florida Launches Joyful Holiday Caravan Across Florida

Updated Category News Views 239

Coke Florida Kicks Off Holiday Spirit with Caravan Tour Coca-Cola Beverages Florida, LLC (Coke Florida) is thrilled to share that its beloved annual "Holiday Caravan" is set to return. This event, which has become an essential part of the holiday season, features the iconic Coca-Cola red delivery truck decked out in festive cheer. Families will enjoy complimentary samples...

Continue Reading
Nexxen to Join RBC Conference, Share Insights on Technology

Updated Category News Views 68

Nexxen's Upcoming Participation at RBC Global Conference Nexxen International Ltd. (AIM/NASDAQ: NEXN), a leading global advertising technology platform, is geared up to take part in a significant event, the RBC Global Technology, Internet, Media and Telecommunications Conference. This event provides a stellar opportunity for companies to connect with investors and share...

Continue Reading
GayVeterans.us Obtains 501(c)(3) Status to Broaden Support

Updated Category News Views 125

GayVeterans.us Achieves 501(c)(3) Tax Exempt Status GayVeteransUS-Inc. has recently been granted 501(c)(3) tax-exempt status, marking a significant milestone for the organization. This designation enables supporters to make tax-deductible contributions, strengthening the community's ability to provide enhanced resources and support. The dedication of veteran volunteers...

Continue Reading
Virbac Expands Portfolio with Acquisition of Felanorm Solution

Updated Category News Views 130

Virbac Enhances Its Offerings with Felanorm Acquisition Virbac has announced a significant acquisition that marks a pivotal moment in its commitment to improving the health and quality of life for senior cats. This globally recognized drug is aimed at treating feline hyperthyroidism, a condition that is becoming increasingly common in older cats. Understanding Feline...

Continue Reading